You just read:

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

News provided by

Protagonist Therapeutics, Inc.

Jan 06, 2020, 07:00 ET